SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001047469-20-000182
Filing Date
2020-01-10
Accepted
2020-01-10 17:10:15
Documents
10

Document Format Files

Seq Description Document Type Size
1 S-3 a2240429zs-3.htm S-3 339262
2 EX-4.1 a2240429zex-4_1.htm EX-4.1 520615
3 EX-4.3 a2240429zex-4_3.htm EX-4.3 178136
4 EX-4.4 a2240429zex-4_4.htm EX-4.4 172581
5 EX-4.5 a2240429zex-4_5.htm EX-4.5 156323
6 EX-5.1 a2240429zex-5_1.htm EX-5.1 17212
7 EX-5.2 a2240429zex-5_2.htm EX-5.2 25314
8 EX-23.1 a2240429zex-23_1.htm EX-23.1 2801
9 G178942.JPG g178942.jpg GRAPHIC 25876
10 G15562KOI001.GIF g15562koi001.gif GRAPHIC 2343
  Complete submission text file 0001047469-20-000182.txt   1452674
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: S-3 | Act: 33 | File No.: 333-235889 | Film No.: 20521929
SIC: 2834 Pharmaceutical Preparations